VEGF obstructs the lungs

Article Abstract:

Nearly 30 percent of population in the United States suffers from allergies including asthma, which ramps up annual health care cost of 18 billion dollars. Type 2 T helper cells that help in the generation and orchestration of allergic responses, and a critical regulator of new blood vessel formation-vascular endothelial growth factor (VEGF) cooperate in the development of allergic lung responses.

Vascular endothelial growth factor

---

A chimeric human-cat fusion protein blocks cat-induced allergy

Article Abstract:

A chimeric human-cat fusion protein composed of a truncated human IgG Fcgamma1and the major cat allergen Fel d1as a proof of concept for a new approach to allergy immunotherapy is designed and tested. Chimeric human Fcgamma-allergen fusion proteins may provide a new therapeutic platform for the immune-based therapy of allergic disease.

Prevention

---

Nipping cat allergy with fusion proteins

Article Abstract:

A new potential treatment is established for a general approach that might be applied not only to severe cat allergy but also to a wide range of allergies. A new approach, involving fusing the allergen to a protein that modulates the immune responses, could provide a more effective and safer alternative.

Cats, Allergens, Cat diseases

Similar abstracts:

• Abstracts: Power to the people. Winning the drugs war. French researchers face winter of discontent
• Abstracts: Patient involvement in the management of leg ulcers. Caring for a patient with malodorous leg ulcers. Leg ulcer assessment techniques in a remote rural area
• Abstracts: Assessing mixed venous and arterial leg ulcers. Diagnosing, treating, and delivering care for people with venous leg ulcers
• Abstracts: The incidence of Kaposi sarcoma among injection drug users with AIDS in the United States. Survival after cancer diagnosis in persons with AIDS
• Abstracts: Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. Efficacy and tolerability of a nucleoside reserve transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.